The first report of the outcome of liver transplantation (Ltx) for hereditary transthyretin (h-TTR) amyloidosis, previously designated familial amyloid polyneuropathy (FAP), was published in 1993 in the Lancet,1 and it described the outcome for 4 patients with the TTR Val30Met mutation who had been followed up for 1 to 2 years after the procedure. The impression was that the procedure was successful, with symptomatic improvement for some patients, and that a regression of the amyloid load, measured by serum amyloid protein scintigraphy, could be observed. This was a major achievement against this previously intractable fatal systemic amyloid disease. However, subsequent analysis over the following years disclosed less favorable outcomes for those carrying non-TTR Val30Met mutations2-4 and also for malnourished patients and those with longstanding and advanced disease.5-7 Differences between patients with early onset compared to those with late onset of the disease were observed.8 Heart complications after transplantation were the dominant problem.2-4,9,10 It is obvious that careful selection of patients is necessary to achieve acceptable outcomes.
The Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) was established in 1995 by a group of investigators taking part in the First International Workshop on Liver Transplantation for Familial Amyloidotic Polyneuropathy, held at Karolinska Institutet in Stockholm, Sweden in 1993. The purpose was to monitor international experience with Ltx for this indication and to promote collaboration and ultimately improve patient selection and results. The registry now contains accumulated survival data from more than 20 years of follow-up of transplanted h-TTR amyloidosis patients from 1990 onward. These data are now of vital importance, with the arrival of medical therapy for the disease. The first compound, tafamidis, is a stabilizing agent that helps to prevent the tetrameric TTRs from dissociating into monomers and assembling into amyloid fibrils.11 However, several other treatment modalities, including silencing RNA,12 and diflunisal,13 are going into clinical trials. Tafamidis demonstrated efficacy in slowing down the progression rate of the disease in a controlled trial,14 and it is now approved by the European Medical Agency for treatment of h-TTR amyloidosis at early stages of the disease. However, its efficacy for long-term treatment has not been assessed, and the cost appears to be substantially higher than that of Ltx. Recently, it was suggested that patients with early-stage h-TTR amyloidosis should initially be treated by tafamidis, and if their disease progressed, they should be considered for Ltx.15 However, this strategy is questionable because the patient would be in a less favorable position for transplantation with more-advanced disease.
The efficacy of new treatments should principally be compared with currently available treatment modalities. It appears to be impossible to carry out a comparative study between Ltx, which is the currently accepted treatment for h-TTR, and the new medical treatment, tafamidis. However, Ltx remains the gold standard against which new treatments should be measured, and the long-term outcome for Ltx patients can be assessed from the data in FAPWTR. The aim of the present study was to evaluate the mortality of h-TTR amyloidosis patients who underwent Ltx, based on data in the FAPWTR collected over the course of 20 years.
MATERIALS AND METHODS
Seventy-seven centers in 19 countries report data related to Ltx for TTR amyloidosis to the FAPWTR. An initial report is given at the time of Ltx. In addition, retransplantation, patient death, or loss to follow-up, as well as if an additional organ transplantation is performed, such as heart or kidney combinations with a Ltx, are also reported. Participating centers are requested to provide annual follow-up data on patients who were previously reported to the register. Information regarding demographics, heredity, type of TTR mutation, clinical manifestations, and peripheral and autonomic neuropathy are recorded. Patient weight, height, and serum albumin are recorded for calculation of the modified body mass index (mBMI). The pretransplant value of this index has been reported to correlate with the prognosis after transplantation.18 The index is calculated by multiplying the BMI of the patient by the level of serum albumin; thus, there is compensation for the presence of oedema in malnourished patients, which may yield a falsely high BMI.
Results from the FAPWTR are reported back to collaborating members on a yearly basis. The FAPWTR data are also to some extent shown on its homepage (www.fapwtr.org). It is also possible to download report forms from the homepage.
In the present analysis, patients who were reported to FAPWTR until December 2010, with a minimum follow-up of 1 year, were included. Patients not reported as dead and with no follow-up after January 1, 2010 were regarded as lost to follow-up.
To test for differences between means of normally distributed data from different patient categories, Student t test was used. Patient survival probabilities were calculated by Kaplan-Meier estimation. The log-rank test (Mantel Cox) was used to test the equality of survival patterns among different categories of patients. All statistical tests were 2-sided and conducted at the 0.05 significance level. Unless stated otherwise, statistics are presented as mean ± standard deviation. Univariable analysis was performed using the logistic regression model and significant variables were put into the Cox multivariate proportional hazards model to determine the risk factors associated with survival. The assumptions of proportional hazards were checked by analyzing plots of the log cumulative hazard stratified by factors used in the model and by analyzing plots of Schoenfeld residuals versus survival time. Variables were added stepwise to the model, selecting the most statistically significant variable first. Then an analysis was done to find the following variable that, together with the first variable, best prognosticated survival. Variables were added until no improvement in prediction was seen as assessed by an increase in the log-likelihood value. Finally, findings based on stepwise addition were confirmed by a stepwise deletion. This was done by forcing all variables into the model after which variables were successively eliminated, based on which of the remaining variables delivered the smallest reduction in the log-likelihood value. Odds ratios and hazard ratios with their P values were estimated between different groups and reported in Table 2. Covariates were tested for independence, and no significant multicolinearity was identified for the covariates.
Approximately 125 liver transplants were performed and reported yearly worldwide for h-TTR amyloidosis, with a potential reduction in transplantation activity over the last 2 years (Figure 1). A total of 1940 patients underwent 2127 Ltxs, and 561 patient deaths were reported to the registry. One hundred and eighty-eight retransplantations were performed in 170 patients. Arterial thrombosis (92/188, 48.9%) followed by primary non-function (31/188, 16.5%) were the most common reasons for retransplantation with retransplantation performed median 10 and 2 days after the initial transplantation, respectively. As a curiosity, one patient was retransplanted because of FAP in the deceased donor liver, not known at time of first transplantation. There were 33 reported transplants for combined liver and kidney transplantation, and 50 combined liver and heart transplants. Three patients were reported to have undergone combined liver, heart, and kidney transplantation. Patients undergoing combined transplantation were generally older than those only being treated with Ltx for TTR amyloidosis and carrying a non-TTR Val30Met mutation (Table 1). Overall 20-year survival after transplantation, all mutations included, was 55.3% (Figure 2). The expected mortality rate decreased on average by approximately 4% per year between 1990 and 2010. Improved survival in TTR Val30Met patients was most pronounced during the first 5-year period, whereas non-TTR Val30Met patient survival improved throughout the 20-year period. The gap in long-term survival between TTR Val30Met and non-TTR Val30Met therefore decreased over the years, but it was still significant (P < 0.05).
Some regional differences were seen for the most common mutation, TTR Val30Met. The highest percentage of late onset, defined as onset of clinical symptoms of TTR amyloidosis after the age of 50 years, was found in Swedish patients. Lowest age at onset of disease was seen in Brazil. The highest percentage of peripheral neuropathy (sensory loss as main initial symptoms) was reported in French and Spanish patients, whereas the highest percentage of autonomic neuropathy and/or GI dysfunction as main initial symptoms was reported from Japan. The overall highest transplantation activity was reported from Portugal.
Outcome of Multivariate Analysis
The impacts of sex, duration of disease, mBMI, early versus late onset, and TTR Val30Met versus non-TTR Val30Met mutation were examined by multivariate analysis (Table 2). The analysis revealed that high mBMI, early onset of disease, short disease duration, and presence of the Val30Met mutation were all significantly related to decreased mortality, both for the whole group of patients and for the subgroups. Female sex was related to increased survival for the late-onset patient group only.
TTR Mutation and Transplantation
Over the years, an increasing number of patients with new TTR mutations underwent Ltx. In 1995, 16 different TTR mutations had been identified among patients who were undergoing Ltx. In 2010, the corresponding figure was 55 mutations. Throughout the 20-year period, TTR Val30Met was the most common mutation among TTR patients who underwent Ltx. Although pretransplant mBMI as a measurement of the patients’ nutritional status gradually increased during the observation period, mean age at time of transplantation, and duration of disease before transplantation successively declined (Figure 1). In Table 1, some important differences between the TTR Val30Met patients and non-TTR Val30Met patients are shown. The proportion of male patients was smaller, and the age at transplantation indicated a younger population of patients in the TTR Val30Met group. In addition, non-TTR Val30Met patients were more likely to undergo combined transplantations. Table 3 shows the outcome of patients with the most common non-TTR Val30Met mutations, as well as their sex and age distribution and whether a combined heart-liver transplant was performed or not.
Age of Onset of Clinical Symptoms of TTR Amyloidosis
In late-onset patients, that is, onset of symptoms of disease after the age of 50 years, no differences were seen between TTR Val30Met and non-TTR Val30Met patients in the proportion of men and women, age at onset, duration of symptoms, or mBMI at transplantation. Moreover, survival after Ltx in patients with late onset was similar between TTR Val30Met and non-TTR Val30Met patients, but was significantly reduced compared to early-onset TTR Val30Met patients (Figure 2). Male late-onset patients had a markedly reduced 10-year survival compared to early-onset male patients (28% and 78%, respectively) (Table 1). The mortality rate in late-onset men was 156.9% that of late-onset women (P = 0.014). Early-onset patients, all mutations, had an expected mortality rate of 37.8% that of the late-onset group (P < 0.001). Furthermore, TTR Val30Met patients had an expected mortality rate of 61% that of non-TTR Val30 Met patients (P < 0.001) (Table 2).
Duration of Disease Before Transplantation
Duration of disease before transplantation had a significant impact on survival after transplantation (Table 2). Thus, a 1-year increased duration of the disease increased the mortality by 10.9% (P < 0.001). Different effects of duration were seen between the early- and late-onset groups: 19.1% (P < 0.001) increased mortality per year for the early-onset group compared to 5.1% (P < 0.05) for the late-onset group.
Nutritional Status at Time of Transplantation
Because low mBMI at transplantation has been shown to be associated with worse posttransplantation survival in FAP patients, we analyzed survival outcome in patients using 4 different mBMI levels, less than 600, 600–699, 700–799, 800–899, and 900 or higher, respectively. A log rank test was run to determine if there were differences in the survival distribution for the different levels of mBMI. The survival distributions for the five levels of mBMI were statistically significantly different (χ2(4) = 28.827, P < 0.0001). In all patients, for each 100-unit increase in mBMI at transplantation, mortality was reduced to 89.1% that of the expected mortality (P < 0.001) (Table 2).
Causes of Death
A total of 561 patient deaths were reported. In 22% of these patients, the cause of death was reported as secondary to septicaemia. Cardiovascular-related deaths occurred in 22% of the cases, and liver-related complications resulted in death in 14%. Intraoperative death represented 3%. When these main causes of death were compared with the European Liver Transplant Registry (ELTR), the causes were comparable, except for cardiac-related deaths: FAPWTR 22% versus ELTR 9%.
Risk Associated With Domino Donation
The 1064 h-TTR amyloidosis patients who donated their liver for domino transplantation had a survival that was similar to that of the 660 patients from the same time period who did not donate.
Since the introduction of LTx for h-TTR amyloidosis, the number of cases reported to the registry increased rapidly up until 2000. Thereafter, it remained relatively stable, with an apparent increase in 2007 to 2008 and then a decline; the latter may have been related to the approval, by the European medical product agency, of tafamidis for the treatment of early-stage (able to walk without support) neuropathic TTR amyloidosis. Because tafamidis is prescribed to patients in the early stages of the disease, it will take considerable time before an improvement in survival associated with tafamidis treatment can be proven.
In the present analysis, a 20-year survival rate of more than 50% was found after transplantation in h-TTR amyloid patients; this is a considerable improvement compared to that of previous reports on the natural history of the disease, in which the survival from onset of disease was approximately 10 to 15 years.16–18 Considering the difference between calculating survival from onset of disease and from time of transplantation, as was used in this investigation, the improvement in survival is even more impressive. In our analysis, all patients with h-TTR amyloidosis, irrespective of mutation, were included, as were those with advanced disease and/or poor nutritional status. The majority of these types of patients are no longer readily accepted for transplantation, as shown by the successively shorter disease duration, increased mBMI, and decreased age of the transplanted patients observed in the registry during the observation period. This optimization of selection criteria is also reflected in the rapidly improved outcome for early-onset TTR Val30Met patients, in whom the 15-year survival rate was close to 80%. During this 2 decade study period, several modifications to immunosuppressive protocols were of course implemented, which may have contributed to the observed improved survival. This variable could, however, not be analyzed because data on immunosuppression is not reported to the FAPWTR.
Improved survival during the study observation period was observed for non-TTR Val30Met patients. This may be related to patient selection, based on the knowledge of posttransplant development of amyloid cardiomyopathy observed in many patients with non-TTR Val30Met mutations, for which a combined liver and heart transplantation may be a viable alternative.2-4,19,20 However, the steadily increasing number of different mutations in the registry and a gradual improvement in the survival of patients with these mutations also points to the influence of a learning curve for the different transplant centers because non-TTR Val30Met patients are often reported from centers outside the endemic TTR Val30Met areas; thus, from centers where Ltx for hTTR amyloidosis is relatively infrequently performed. However, the outcome for patients with non-TTR Val30Met mutations, such as Ser77Tyr, Thr60Ala, and Ser50Arg, is still disappointing, and can be explained neither by their generally higher age because the mortality was similar for late- and early-onset patients, nor by impaired nutritional status, because the mBMI was significantly higher in the non-TTR Val30Met group of patients. In addition, disease duration before transplantation was similar for both groups of patients. However, it should be noted that for several non-TTRVal30Met mutations, such as Val71Ala and Leu58His and especially Leu111Met, Ltx with or without simultaneous heart transplantation was successful. Considering that cardiomyopathy dominates the clinical presentation in patients with the Leu111Met mutation,21 the outcome is surprisingly good.
Previous reports have identified various risk factors, and several were confirmed by our analysis.6,22,23 Risk factors analyzed that had an independent negative impact on survival included: non-TTR Val30Met mutation, late onset, advanced disease reflected by long disease duration before transplantation, and malnutrition measured by the mBMI.
An important finding was the close to 20% annual increase in mortality risk noted for early-onset TTR Val30Met patients waiting for Ltx. This needs to be taken into consideration when pharmacotherapy is considered for early-onset patients, who have the best expected outcome after Ltx and who are also subject to substantially increased risk if pharmacotherapy proves to be inefficient.
The presence of h-TTR in the family history was not a risk factor, and neither was sex. However, in an analysis of survival in the subgroup of late-onset patients, female sex was associated with significantly better survival compared to male sex, for which survival was no different from that expected for nontransplanted patients. This sex difference for late-onset patients was previously reported from Sweden.8 We do not know why there are such marked differences between genders and between early- and late-onset patients, or between TTR Val30Met and other mutations. However, differences in amyloid fibril composition have been found between early- and late-onset TTR Val30Met patients and also between early-onset TTR Val30Met patients and other mutations: late-onset TTR Val30Met patients and non-TTR Val30Met patients display a fibril composition similar to that noted in senile systemic amyloidosis (SSA).24,25 The SSA is caused by amyloid fibril formation from wild-type TTR, and it is therefore not affected by Ltx. In addition, an increase in or development of amyloid cardiomyopathy after transplantation has lately been shown to occur predominantly in patients with an amyloid fibril composition similar to that of SSA.26
The importance of heart complications with regard to outcome after transplantation is reflected by the causes of death. Cardiac-related death was markedly more frequent for hTTR amyloid patients compared to that reported to the ELTR for Ltx in patients with nonamyloid diseases.
The FAPWTR registry does not report in detail on symptomatic changes after Ltx, but for TTR Val30Met patients, especially early-onset patients, the disease progression appears to come to a halt.5,27 However, Ltx does not affect variant TTR production in the eye or brain. Several reports have been published on the development of vitreous opacities and glaucoma after Ltx.28,29 The development of CNS complications is still an open question, but patients carrying the rare occulomeningeal h-TTR mutations, such as Gly53Glu, are not helped by Ltx.30 In addition, the development of conduction disturbances necessitating pacemaker treatment has been reported for early-onset h-TTR Val30Met patients after the procedure.9 Consequently, prophylactic pacemaker insertion before transplantation is performed at several centers.
Data from the FAPWTR clearly show that using the livers of h-TTR patients for other patients in need of a liver transplant has no impact on the survival of the donors. Recently, the development of TTR amyloidosis in domino liver recipients was reported,22,31 but TTR amyloid livers are still an important source of organs for selected patients, such as elderly patients, patients with liver cancer, in whom graft loss or patient death is more likely to occur from the recipient’s original disorder than from the transfer of TTR amyloidosis by a variant TTR liver.
In summary, long-term survival after Ltx for h-TTR amyloidosis is excellent in well-selected patients. Good nutritional status, short duration of disease at the time of Ltx, and early onset of the disease are significant independent factors for survival. The TTR Val30Met patients had a better outcome compared to non-TTR Val30Met patients. The risk of delaying Ltx by testing alternative treatments, especially in early-onset TTR Val30Met patients, requires further consideration.
Acknowledgements to FAPWTR Participating Centers:
Portugal: Hospital Curry Cabral, Lisbon. Hospital de Santo António, Porto. Coimbra University Hospital, Coimbra. Hospital de San João*, Porto. France: Hospital Paul Brousse/Kremlin Bicêtre, Villejuif. Hospital Hautepierre, Strasbourg. Hospital Edouard Herriot, Lyon. Hospital de la Conception, Marseille. Hospital Beaujon, Clichy. Pellegrin Hospital, Bordeaux. Sweden: Karolinska University Hospital Huddinge, Stockholm. Sahlgrenska University Hospital, Gothenburg. USA: Mayo Clinic, Rochester. Lahey Clinic Medical Center, Burlington. NEDH/Harvard Medical School*, Boston. UCSF Medical Center, San Francisco. Jackson Memorial Hospital, Miami. Thomas E Starzl Transplant Institute, Pittsburgh. Mayo Clinic, Phoenix. University of North Carolina Hospitals, Chapel Hill. The Penn Transplant Center, Philadelphia. University of Maryland Medical Center, Baltimore. Medical University of South Carolina, Charleston. Northwestern Memorial Hospital*, Chicago. Cleveland Clinic Foundation, Cleveland. University Hospitals of Cleveland, Cleveland. University Hospital of Colorado, Aurora. Brazil: Hospital Israelita Albert Einstein, Sao Paulo. Federal University of Rio de Janeiro, Rio de Janeiro. Oswaldo Cruz University Hospital, Recife. Federal University of Paraná, Curitiba. Spain: Hospital de Bellvitge, Barcelona. Hospital Virgen de la Arrixaca, Murcia. University Hospital Virgen del Rocio, Seville. Hospital Clinic, Barcelona. Hospital de Cruces Barakaldo, Vizcaya. Clinica Universitaria, Pamplona. Hospital Vall D’Hebron, Barcelona. Hospital Ramón y Cajal, Madrid. La Fe Hospital, Valencia. Japan: Shinshu University Hospital, Matsumoto. Kumamoto University Hospital, Kumamoto. Nagoya University Hospital, Nagoya. Tokyo University Hospital, Tokyo. Kyushu University Hospital, Fukuoka. Hokkaido University Hospital, Sapporo. Kyoto University Hospital, Kyoto. Niigata University Hospital, Niigata. Keio University, Tokyo. UK: King’s College Hospital, London. Royal Post Graduate Medical School, London. Royal Free Hospital, London. Queen Elizabeth Hospital, Birmingham. Germany: Der Johannes Gutenberg Universität, Mainz. Klinikum der Universität, Heidelberg. Medizinische Hochschule, Hannover. Klinikum der Universität, Tübingen. Universitätsklinikum, Münster. Chirurgische Universitätsklinik, Freiburg. Italy: Hospital Bellaria, Bologna. National Cancer Institute, Milan. Australia: Queensland LTS, Brisbane. Royal Prince Alfred Hospital, Sydney. South Australia Liver Transplant Unit, Bedford Park. Switzerland: Hospital Cantonal, Geneva. Inselspital, Bern. Netherlands: University Medical Center, Groningen. Belgium: UCL St Luc, Brussels. University Hospital, Gent. University of Liège, Liège. Argentina: Hospital C Argerich, Buenos Aires. Hospital Italiano, Buenos Aires. Canada: London Health Science Center, London. Toronto General Hospital, Toronto. Denmark: Copenhagen University Hospital, Copenhagen. China: Queen Mary Hospital, Hong Kong. Singapore: Singapore General Hospital.
*No longer an active participant in the FAPWTR.
1. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet
1993; 341: 1113.
2. Dubrey SW, Davidoff R, Skinner M, et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation
1997; 64: 74.
3. Garcia-Herola A, Prieto M, Pascual S, et al. Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by tyrosine-77 transthyretin variant. Liver Transpl Surg
1999; 5: 246.
4. Stangou AJ, Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation
1998; 66: 229.
5. Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain
2000; 123: 1495.
6. Bittencourt PL, Couto CA, Farias AQ, et al. Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil. Liver Transpl
2002; 8: 34.
7. Suhr OB, Holmgren G, Steen L, et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation
1995; 60: 933.
8. Okamoto S, Wixner J, Obayashi K, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients’ survival. Liver Transpl
2009; 15: 1229.
9. Hornsten R, Wiklund U, Olofsson BO, et al. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation
2004; 78: 112.
10. Olofsson BO, Backman C, Karp K, et al. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation
2002; 73: 745.
11. Hammarstrom P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science
2003; 299: 713.
12. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med
2013; 369: 819.
13. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA
2013; 310 (24): 2658.
14. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology
2012; 79: 785.
15. Said G, Grippon S, Kirkpatrick P. Tafamidis. Nat Rev Drug Discov
2012; 11: 185.
16. Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl
1976; 590: 1.
17. Coutinho P, da Silva AM, Lima JK, et al. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. International congress series no 497. In: Glenner GG, e Costa PP, de Freitas AF, eds. Amyloid and amyloidosis
. Amsterdam-Oxford-Princeton: Excerpta Medica, 1979: 88.
18. Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med
1994; 235: 479.
19. Nelson LM, Penninga L, Sander K, et al. Long-term outcome in patients treated with combined heart and liver transplantation for familial amyloidotic cardiomyopathy. Clin Transplant
2013; 27: 203.
20. Sharma P, Perri RE, Sirven JE, et al. Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transpl
2003; 9: 1273.
21. Ranlov I, Alves IL, Ranlov PJ, et al. A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers [see comments]. Am J Med
1992; 93: 3.
22. Adams D, Lacroix C, Antonini T, et al. Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients. Amyloid
2011; 18 (Suppl 1): 174.
23. Suhr OB, Ericzon BG, Friman S. Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transpl
2002; 8: 787.
24. Ihse E, Rapezzi C, Merlini G, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid
2013; 20: 142.
25. Ihse E, Ybo A, Suhr O, et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol
2008; 216: 253.
26. Gustafsson S, Ihse E, Henein MY, et al. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation
2012; 93: 1017.
27. Ikeda S, Takei Y, Yanagisawa N, et al. Peripheral nerves regenerated in familial amyloid polyneuropathy after liver transplantation. Ann Intern Med
1997; 127 (8 Pt 1): 618.
28. Ando Y, Ando E, Tanaka Y, et al. De novo amyloid synthesis in ocular tissue in familial amyloidotic polyneuropathy after liver transplantation [letter]. Transplantation
1996; 62: 1037.
29. Sandgren O, Kjellgren D, Suhr OB. Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy. Acta Ophthalmol
2008; 86: 520.
30. De Carolis P, Galeotti M, Ficarra G, et al. Fatal cerebral haemorrhage after liver transplantation in a patient with transthyretin variant (gly53glu) amyloidosis. Neurol Sci
2006; 27: 352.
31. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med
2005; 352: 2356.